Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.67

Astria Therapeutics, Inc. (NASDAQ:ATXS) has received an average rating of “Buy” from the eight brokerages that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $25.67.

A number of brokerages have recently commented on ATXS. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities started coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, February 27th. Finally, Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $5.82 on Tuesday. Astria Therapeutics has a 1 year low of $5.75 and a 1 year high of $16.90. The stock has a market capitalization of $328.45 million, a PE ratio of -2.78 and a beta of 0.69. The company’s 50 day simple moving average is $7.32 and its two-hundred day simple moving average is $9.65.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors have recently bought and sold shares of ATXS. Fcpm Iii Services B.V. bought a new position in Astria Therapeutics during the fourth quarter valued at $25,680,000. FMR LLC lifted its position in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. Vestal Point Capital LP lifted its position in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after purchasing an additional 750,000 shares during the last quarter. Redmile Group LLC purchased a new stake in shares of Astria Therapeutics in the third quarter valued at $3,423,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Astria Therapeutics by 152.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after buying an additional 189,727 shares during the period. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.